418 related articles for article (PubMed ID: 30426396)
1. Risks of hepatocellular carcinoma and cirrhosis-associated complications in patients with rheumatoid arthritis: a 10-year population-based cohort study in Taiwan.
Hsu CS; Lang HC; Huang KY; Chao YC; Chen CL
Hepatol Int; 2018 Nov; 12(6):531-543. PubMed ID: 30426396
[TBL] [Abstract][Full Text] [Related]
2. Association between complicated liver cirrhosis and the risk of hepatocellular carcinoma in Taiwan.
Hung TH; Liang CM; Hsu CN; Tai WC; Tsai KL; Ku MK; Wang JW; Tseng KL; Yuan LT; Nguang SH; Yang SC; Wu CK; Hsu PI; Wu DC; Chuah SK
PLoS One; 2017; 12(7):e0181858. PubMed ID: 28742130
[TBL] [Abstract][Full Text] [Related]
3. Diabetes Is Associated with Clinical Decompensation Events in Patients with Cirrhosis.
Liu TL; Trogdon J; Weinberger M; Fried B; Barritt AS
Dig Dis Sci; 2016 Nov; 61(11):3335-3345. PubMed ID: 27480088
[TBL] [Abstract][Full Text] [Related]
4. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
[TBL] [Abstract][Full Text] [Related]
5. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
6. Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy.
Shim JJ; Oh CH; Kim JW; Lee CK; Kim BH
Scand J Gastroenterol; 2017 Sep; 52(9):1029-1036. PubMed ID: 28562104
[TBL] [Abstract][Full Text] [Related]
7. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis.
Chien J; Liu J; Lee MH; Jen CL; Batrla-Utermann R; Lu SN; Wang LY; You SL; Yang HI; Chen CJ
J Gastroenterol Hepatol; 2016 Dec; 31(12):1971-1977. PubMed ID: 27118149
[TBL] [Abstract][Full Text] [Related]
8. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
9. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.
Lai SW; Chen PC; Liao KF; Muo CH; Lin CC; Sung FC
Am J Gastroenterol; 2012 Jan; 107(1):46-52. PubMed ID: 22085817
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology.
Abbas Z; Siddiqui AU; Luck NH; Hassan M; Mirza R; Naqvi A; Rizvi AH
J Pak Med Assoc; 2008 Nov; 58(11):602-7. PubMed ID: 19024130
[TBL] [Abstract][Full Text] [Related]
11. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
[TBL] [Abstract][Full Text] [Related]
12. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients.
D'Amico G; Pasta L; Morabito A; D'Amico M; Caltagirone M; Malizia G; Tinè F; Giannuoli G; Traina M; Vizzini G; Politi F; Luca A; Virdone R; Licata A; Pagliaro L
Aliment Pharmacol Ther; 2014 May; 39(10):1180-93. PubMed ID: 24654740
[TBL] [Abstract][Full Text] [Related]
13. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
Kim WR; Loomba R; Berg T; Aguilar Schall RE; Yee LJ; Dinh PV; Flaherty JF; Martins EB; Therneau TM; Jacobson I; Fung S; Gurel S; Buti M; Marcellin P
Cancer; 2015 Oct; 121(20):3631-8. PubMed ID: 26177866
[TBL] [Abstract][Full Text] [Related]
14. Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection.
Wu CY; Chen YJ; Ho HJ; Hsu YC; Kuo KN; Wu MS; Lin JT
JAMA; 2012 Nov; 308(18):1906-14. PubMed ID: 23162861
[TBL] [Abstract][Full Text] [Related]
15. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses.
Wang CS; Yao WJ; Chang TT; Wang ST; Chou P
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2054-60. PubMed ID: 19549812
[TBL] [Abstract][Full Text] [Related]
16. Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C.
Hedenstierna M; Nangarhari A; Weiland O; Aleman S
Clin Infect Dis; 2016 Sep; 63(6):723-9. PubMed ID: 27282709
[TBL] [Abstract][Full Text] [Related]
17. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).
Trinchet JC; Bourcier V; Chaffaut C; Ait Ahmed M; Allam S; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Goria O; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Buffet C; Bacq Y; Wartelle C; Dao T; Benhamou Y; Pilette C; Silvain C; Christidis C; Capron D; Thiefin G; Hillaire S; Di Martino V; Nahon P; Chevret S;
Hepatology; 2015 Sep; 62(3):737-50. PubMed ID: 25678021
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant use and hepatocellular carcinoma in patients with hepatitis C who had received interferon therapy: A population-based cohort study.
Chen VC; Lu ML; Yang YH; Weng JC; Chang CC
J Affect Disord; 2019 Jun; 253():147-153. PubMed ID: 31035215
[TBL] [Abstract][Full Text] [Related]
19. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E;
Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138
[TBL] [Abstract][Full Text] [Related]
20. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
